Coherus Oncology reports Q3 2025 net revenue of $11.2 million and net loss of $38.9 million

Reuters

2025/11/07

Coherus Oncology reports Q3 2025 net revenue of $11.2 million and net loss of $38.9 million

Coherus Oncology Inc. reported third quarter 2025 net revenue from continuing operations of $11.6 million, up from $6.1 million in the same period in 2024. Net revenue for the nine months ended September 30, 2025 was $29.4 million, compared to $18.7 million for the same period in 2024. LOQTORZI net product revenue increased by $5.3 million year-over-year for the quarter, primarily due to volume growth following its launch in December 2023. Non-GAAP net loss from continuing operations for the third quarter was $38.9 million, or $(0.33) per diluted share, compared to $40.0 million, or $(0.35) per diluted share in the prior year period. Cash, cash equivalents, and marketable securities totaled $191.7 million at the end of the quarter. Selling, general and administrative expenses for the quarter were $24.9 million, down from $28.1 million in the same quarter of 2024, reflecting lower headcount and decreased operating costs following recent divestitures. The CHS-114 clinical program was expanded to include colorectal cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570915-en) on November 06, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2581048956"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581048956\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581048956?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581048956","market":"nz","top_or_hot":-1,"title":"Coherus Oncology reports Q3 2025 net revenue of $11.2 million and net loss of $38.9 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Coherus Oncology reports Q3 2025 net revenue of $11.2 million and net loss of $38.9 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Coherus Oncology Inc. reported third quarter 2025 net revenue from continuing operations of $11.6 million, up from $6.1 million in the same period in 2024. Net revenue for the nine months ended September 30, 2025 was $29.4 million, compared to $18.7 million for the same period in 2024. LOQTORZI net product revenue increased by $5.3 million year-over-year for the quarter, primarily due to volume growth following its launch in December 2023. Non-GAAP net loss from continuing operations for the third quarter was $38.9 million, or $(0.33) per diluted share, compared to $40.0 million, or $(0.35) per diluted share in the prior year period. Cash, cash equivalents, and marketable securities totaled $191.7 million at the end of the quarter. Selling, general and administrative expenses for the quarter were $24.9 million, down from $28.1 million in the same quarter of 2024, reflecting lower headcount and decreased operating costs following recent divestitures. The CHS-114 clinical program was expanded to include colorectal cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570915-en) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coherus Oncology reports Q3 2025 net revenue of $11.2 million and net loss of $38.9 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoherus Oncology reports Q3 2025 net revenue of $11.2 million and net loss of $38.9 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Coherus Oncology reports Q3 2025 net revenue of $11.2 million and net loss of $38.9 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Coherus Oncology Inc. reported third quarter 2025 net revenue from continuing operations of $11.6 million, up from $6.1 million in the same period in 2024. Net revenue for the nine months ended September 30, 2025 was $29.4 million, compared to $18.7 million for the same period in 2024. LOQTORZI net product revenue increased by $5.3 million year-over-year for the quarter, primarily due to volume growth following its launch in December 2023. Non-GAAP net loss from continuing operations for the third quarter was $38.9 million, or $(0.33) per diluted share, compared to $40.0 million, or $(0.35) per diluted share in the prior year period. Cash, cash equivalents, and marketable securities totaled $191.7 million at the end of the quarter. Selling, general and administrative expenses for the quarter were $24.9 million, down from $28.1 million in the same quarter of 2024, reflecting lower headcount and decreased operating costs following recent divestitures. The CHS-114 clinical program was expanded to include colorectal cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570915-en) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKPKM429.USD","symbol_name":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL5CxBZk:1","article_id":"2581048956","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581048956","pubTimestamp":1762464079,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Coherus Oncology Inc. reported third quarter 2025 net revenue from continuing operations of $11.6 million, up from $6.1 million in the same period in 2024. Net revenue for the nine months ended September 30, 2025 was $29.4 million, compared to $18.7 million for the same period in 2024. LOQTORZI net product revenue increased by $5.3 million year-over-year for the quarter, primarily due to volume growth following its launch in December 2023. Non-GAAP net loss from continuing operations for the third quarter was $38.9 million, or $ per diluted share, compared to $40.0 million, or $ per diluted share in the prior year period. Cash, cash equivalents, and marketable securities totaled $191.7 million at the end of the quarter. Selling, general and administrative expenses for the quarter were $24.9 million, down from $28.1 million in the same quarter of 2024, reflecting lower headcount and decreased operating costs following recent divestitures. The CHS-114 clinical program was expanded to inc","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","CHRS":"Coherus Biosciences","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4139":"生物科技","BK4535":"淡马锡持仓","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"Coherus Oncology报告2025年第三季度净收入为1120万美元，净亏损为3890万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"CHRS":0.9},"content_text":"Coherus Oncology reports Q3 2025 net revenue of $11.2 million and net loss of $38.9 million\n    \n\n        Coherus Oncology Inc. reported third quarter 2025 net revenue from continuing operations of $11.6 million, up from $6.1 million in the same period in 2024. Net revenue for the nine months ended September 30, 2025 was $29.4 million, compared to $18.7 million for the same period in 2024. LOQTORZI net product revenue increased by $5.3 million year-over-year for the quarter, primarily due to volume growth following its launch in December 2023. Non-GAAP net loss from continuing operations for the third quarter was $38.9 million, or $(0.33) per diluted share, compared to $40.0 million, or $(0.35) per diluted share in the prior year period. Cash, cash equivalents, and marketable securities totaled $191.7 million at the end of the quarter. Selling, general and administrative expenses for the quarter were $24.9 million, down from $28.1 million in the same quarter of 2024, reflecting lower headcount and decreased operating costs following recent divestitures. The CHS-114 clinical program was expanded to include colorectal cancer.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570915-en) on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}